Core Scientific, Inc. (CORZ) recently garnered a “Buy” rating from Kevin Dede of HC Wainwright & Co., reflecting a bullish outlook on the stock with a price target of $25. With the stock currently trading at $19.87, this upgrade implies substantial upside potential for investors, warranting closer examination of the company’s financial health and market performance.
Recent Price Action
Over the last trading sessions, CORZ has experienced noteworthy movements characterized by a 2.42% increase, closing at $19.87, a change of approximately $0.48. The stock has seen considerable trading activity, with a volume of over 10 million shares traded, though slightly below its average volume of 15.8 million. Core Scientific has exhibited significant volatility, indicated by a beta of 6.60, suggesting that its price movements are more pronounced compared to the overall market. The stock’s performance stands in sharp contrast to its 52-week high of $220.48, emphasizing the decline that has occurred over the year. For context, it has a 52-week low of $2.41, illustrating extreme fluctuations that may either attract risk-tolerant investors or signal caution to more conservative players.
[chart type=’price’ value=’CORZ’]
Short- and Long-Term Performance
Analyzing CORE Scientific’s historical performance reveals a complex picture. Over the past 30 days, the stock has rallied approximately 17.92%, while quarterly returns soared to 50.64%. On a yearly basis, CORZ has posted a gain of 44.83%. Weekly volatility has been measured at 8.11%, reflecting the stock’s tendency for sharp price shifts, while monthly volatility is lower at 6.02%. This level of price variability may capture the attention of traders looking to capitalize on short-term swings but may raise concerns for long-term investors wary of instability.
[chart type=’performance’ value=’CORZ’]
Earnings Analysis
In its most recent earnings report dated August 8, 2025, Core Scientific reported an earnings per share (EPS) of -$0.04, surpassing analyst expectations, which had estimated a loss of -$0.07. This unexpected EPS surprise of approximately 42.86% highlights the company’s potential for improving its financial performance, even within a challenging operating environment. A historical comparison shows that in the prior quarter, CORE Scientific reported an EPS of -$0.10, exceeding an estimate of -$0.12. This trajectory indicates that while the company is still facing losses, its ability to outperform expectations may inspire investor confidence.
[chart type=’income-bar-chart’ value=’CORZ’]
Analyst / Consensus View
The consensus outlook on Core Scientific reflects a mix of caution and optimism. The recent upgrade to a “Buy” rating by HC Wainwright’s Kevin Dede adds to the sentiment that has emerged since the start of the fourth quarter. Among nine total analyst ratings, six categorize the stock as a “Buy,” while three analysts hold on to a “Hold” position, and none recommend selling. The average price target stands at approximately $21.61, with a range that spans from a conservative $15 to an aggressive $26. This consensus indicates a prevailing expectation of price appreciation, which may be further buoyed by potential future earnings upside.
[chart type=’analyst-ratings’ value=’CORZ’]
Stock Grading or Fundamental View
According to the Stocks Telegraph grading system, Core Scientific has received a score of 50. This score encapsulates the company’s current investment profile and overall financial health. A score at this level suggests moderate strengths but also notable weaknesses that may require further scrutiny by prospective investors. Factors worth considering include the company’s operational stability and growth prospects against the backdrop of an evolving cryptocurrency and technology landscape.
[chart type=’st-cards’ value=’CORZ’]
Conclusion
For investors considering Core Scientific, the stock offers an enticing proposition, particularly for those with a higher risk tolerance seeking growth opportunities in volatile market conditions. The recent positive analyst sentiment and potential for upside, as indicated by the “Buy” rating and a price target of $25, mark CORZ as a stock worth monitoring. However, the inherent risks, accentuated by past price volatility and a rollercoaster performance trajectory, necessitate a careful approach. Investors should weigh the potential for short-term gains against the fundamental challenges that remain for Core Scientific as it navigates an unpredictable market environment.